Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Business Wire (Mon, 2-Mar 4:01 PM ET)
Business Wire (Mon, 2-Mar 8:33 AM ET)
Quanterix to Participate in Upcoming Investor Conferences
Business Wire (Thu, 26-Feb 8:33 AM ET)
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Business Wire (Fri, 20-Feb 8:33 AM ET)
Quanterix's Multi-Analyte FDA Submission Could Redefine Alzheimer's Diagnosis
Market Chameleon (Tue, 3-Feb 4:39 AM ET)
Business Wire (Tue, 3-Feb 8:33 AM ET)
Business Wire (Wed, 21-Jan 8:33 AM ET)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 16-Jan 4:01 PM ET)
QTRX Announces CEO Transition With Everett Cunningham, Exceeds 2025 Revenue Outlook
Market Chameleon (Fri, 9-Jan 6:13 AM ET)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Business Wire (Thu, 8-Jan 4:30 PM ET)
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Quanterix trades on the NASDAQ stock market under the symbol QTRX.
As of March 23, 2026, QTRX stock price declined to $3.94 with 1,917,181 million shares trading.
QTRX has a beta of 0.99, meaning it tends to be less sensitive to market movements. QTRX has a correlation of 0.05 to the broad based SPY ETF.
QTRX has a market cap of $184.04 million. This is considered a Micro Cap stock.
Last quarter Quanterix reported $44 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.07.
In the last 3 years, QTRX traded as high as $29.70 and as low as $3.90.
The top ETF exchange traded funds that QTRX belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.
QTRX has underperformed the market in the last year with a price return of -45.6% while the SPY ETF gained +17.9%. QTRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.2% and -22.1%, respectively, while the SPY returned -3.4% and -2.3%, respectively.
QTRX support price is $4.08 and resistance is $4.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTRX shares will trade within this expected range on the day.